Investigating new treatments for conditions related to bradykinin B1 receptors
Official title: Negative allosteric modulators for bradykinin B1 receptors
Funded at University of Texas Hlth Science Center · NIH-10792959 · Data updated 2026-11-12
This study is looking for new ways to help people with asthma, inflammation, and cancer by finding compounds that can calm down a specific receptor in the body that can cause problems when it's too active.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Science Center NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project start | February 21, 2023 |
| Project end | January 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $193,750 |
| NIH project number | 5R21AI172157-02 |
| Project ID | NIH-10792959 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals suffering from asthma, chronic pain, diabetic retinopathy, or certain types of cancer.
✕Less likely to help
Patients who do not have conditions related to bradykinin B1 receptor activity may not benefit from this research.
What this research studies
This research focuses on the bradykinin B1 receptor, which plays a role in various health issues such as asthma, inflammation, and cancer. The project aims to discover new compounds that can effectively reduce the activity of this receptor, which is often overactive in certain diseases. By targeting the receptor's activity, the research seeks to develop better therapeutic options for patients suffering from these conditions. The approach involves identifying negative allosteric modulators that can help manage symptoms and improve patient outcomes.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that alleviate symptoms and improve the quality of life for patients with asthma, cancer, and other related conditions.
How similar studies have gone: While there have been attempts to develop antagonists for bradykinin B1 receptors, this approach of using negative allosteric modulators is relatively novel and has not been extensively tested in clinical settings.
Where this research is happening
-
University of Texas Hlth Science Center
San Antonio, United States Active
Researchers
- Principal investigator: Clarke, William P — University of Texas Hlth Science Center
- Study coordinator: Clarke, William P
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.